Lorraine A. Chantrill, PhD, MBBS, on Gastrointestinal Neuroendocrine Carcinomas: First-Line Treatment With Nab-Paclitaxel Plus Carboplatin
2024 ASCO GI Cancers Symposium
Lorraine A. Chantrill, PhD, MBBS, of Australia’s Wollongong Hospital, New South Wales, discusses phase II findings on the combination of nab-paclitaxel plus carboplatin as a first-line treatment for patients with gastrointestinal neuroendocrine carcinomas. According to Dr. Chantrill, this regimen appears to be active in these tumors and warrants further evaluation in a phase III trial (Abstract 589).
The ASCO Post Staff
Michael K. Gibson, MD, PhD, of Vanderbilt University Medical Center, discusses phase III findings on chemotherapy plus camrelizumab in the ESCORT-NEO trial of patients with resectable esophageal squamous cell carcinoma; and phase III SKYSCRAPER-08 results on first-line tiragolumab plus atezolizumab and chemotherapy in the same patient population (Abstracts LBA244 and 245).
The ASCO Post Staff
Jennifer Yon-Li Wo, MD, of Massachusetts General Hospital, discusses the local failure rate of non-ablative hypofractionated radiation therapy in combination with the immune checkpoint inhibitors ipilimumab and nivolumab compared to ablative SBRT to treat metastatic microsatellite-stable colorectal and pancreatic cancers as a secondary analysis of four prospective trials. Dr. Wo and her team found that, despite using nearly half the radiation dose in those who received immunotherapy, there was no significant difference in local failure rates (Abstract 752).
The ASCO Post Staff
Ian Chau, MD, of The Royal Marsden Hospital, discusses an analysis from the CheckMate 648 study on quality-adjusted time without symptoms and toxicity in patients with unresectable advanced esophageal squamous cell carcinoma. Patients treated with nivolumab plus ipilimumab and nivolumab plus chemotherapy compared with chemotherapy alone experienced longer quality-adjusted survival (Abstract 251).
The ASCO Post Staff
Frank Kullmann, MD, of Germany’s Klinikum Weiden, discusses results from the ALPACA trial, which suggest a dose-reduced regimen with alternating cycles of gemcitabine/nab-paclitaxel and gemcitabine monotherapy after three induction cycles of standard gemcitabine/nab-paclitaxel is feasible and associated with an overall survival comparable to that with standard treatment, as well as improved tolerability (Abstract 605).
The ASCO Post Staff
Dominik P. Modest, MD, of Charité-Universitätsmedizin Berlin, discusses phase III study findings showing sotorasib plus panitumumab vs trifluridine/tipiracil or regorafenib benefits patients with chemorefractory metastatic colorectal cancer in terms of improved clinical outcomes and better self-reported quality of life (Abstract 10).
